A divalent hapten-peptide induces apoptosis in human non-Hodgkin lymphoma cell lines targeted by anti-CD20 x anti-hapten bispecific antibodies

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Brard, Pierre Yves ^a   Karacay, Habibe ^a   Stein, Rhona ^a   Sharkey, Robert M ^a   Mattes, M Jules ^a   Chang, Chien Hsing ^b   Rossi, Edmund A ^b   McBride, William J ^c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE DEXTRO TYROSYLLYSIN(HISTAMINYLSUCCINYLGLYCINE)AMIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLALANYLLYSYL(HISTAMINYLSUCCINYLGLYCINE) DEXTRO TYROSYLLYSIN(HISTAMINYLSUCCINYLGLYCINE)AMIDE; ACETYLPHENYLALANYLLYSYL(DIETHYLENETRIAMINE PENTAACETIC ACID); ACETYLPHENYLALANYLLYSYL(DIETHYLENETRIAMINE PENTAACETIC ACID)TYROSYLLYSIN(DIETHYLENETRIAMINE PENTAACETIC ACID)AMIDE; BISPECIFIC ANTIBODY; CASPASE 3; CD20 ANTIBODY; HAPTEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMP 156; IMP 241; IMP 252; PEPTIDE; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING AFFINITY; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; STAINING;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; APOPTOSIS; CASPASE 3; DIPEPTIDES; ENZYME ACTIVATION; FLOW CYTOMETRY; HAPTENS; HUMANS; LYMPHOMA, NON-HODGKIN; MEMBRANE POTENTIAL, MITOCHONDRIAL;

EID: 34848850864     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1204     Document Type: Conference Paper

References (26)

1. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302.
2. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimericmonoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19:419-27.
3. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.
4. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005;11:5971-80.
5. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-43.
6. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-41.
7. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66.
8. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005;19:1064-9.
9. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized antiCD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78.
10. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841-6.
11. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, et al. Bivalent hapten-bearingp eptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 1997;8:526-33.
12. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63.
13. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935-45s.
14. Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 2002;13:1054-70.
15. Greenwood FC, Hunter WM, Glover JS. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114-23.
16. 188Re-labeled peptide. Bioconjug Chem 2000;11:842-54.
17. Wakabayashi T, Karbowski M. Structural changes of mitochondria related to apoptosis. Biol Signals Recept 2001;10:26-56.
18. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality duringap optosis. FEBS Lett 1997;411:77-82.
19. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46 Suppl 1:115-27S.
20. Sharkey RM, Burton J, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol 2005;1:47-67.
21. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109-21s.
22. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11.
23. Shen S, Forero A, LoBuglio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005;46:642-51.
24. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66:3884-92.
25. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535-43.
26. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-63.